News and Trends 19 Nov 2015
Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?
French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis’s leading product UCART19 for blood cancer. This unusual move only further feeds the rumours of Pfizer’s potential future acquisition of Cellectis. As we’ve discussed before, Cellectis has moved most […]